{"id":"W3081745704","doi":"10.1093/ndt/gfaa234","title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","year":2020,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Janssen Pharmaceuticals; Defense Acquisition Program Administration; Sanofi Genzyme; Merck Sharp and Dohme; Satellite Healthcare; Alexion Pharmaceuticals; University of Glasgow; Steno Diabetes Center Copenhagen; Menarini Group; Novo Nordisk; Omeros Corporation; Astellas Pharma; Cytokinetics; Fresenius Medical Care North America; Daiichi-Sankyo; ReCor Medical; Alnylam Pharmaceuticals; Servier; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; World Health Organization; Ultragenyx Pharmaceutical; GlaxoSmithKline; Amgen; Angion; Pfizer; CSL Behring; AstraZeneca; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Medicine; Dapagliflozin; Kidney disease; Adverse effect; Internal medicine; Baseline (sea); Intensive care medicine; Diabetes mellitus; Endocrinology; Type 2 diabetes","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00144975,0.0005397258,0.001221074,0.0002300685,0.0003004238,0.0005779121,0.0002783309,0.0006173759,0.003986363],"category_scores_gemma":[0.001241814,0.0002118219,0.0009696221,0.0005234159,0.0002621713,0.0004026435,0.0002460109,0.0009207184,0.000382044],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003294189,"about_ca_system_score_gemma":0.0006733933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007971316,"about_ca_topic_score_gemma":0.001577557,"domain_scores_codex":[0.9994911,0.0002041086,0.00005471657,0.0001127516,0.00008331697,0.00005403189],"domain_scores_gemma":[0.9995554,0.00009725113,0.0001574657,0.00002800568,0.00005569117,0.0001061744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8358238,0.005525392,0.09146076,0.003002884,0.005470853,0.00007766178,0.00009031721,0.001150752,0.002215593,0.0002701957,0.008189154,0.04672269],"study_design_scores_gemma":[0.6370884,0.03535657,0.3071295,0.0004870247,0.007810951,0.0002657532,0.00007268889,0.001964654,0.0008335178,0.0007745456,0.008156137,0.00006032152],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679939,0.009927274,0.0008265894,0.0008150955,0.0001883618,0.002594133,0.01235573,0.00004426172,0.005254671],"genre_scores_gemma":[0.9770567,0.002462269,0.001450929,0.0007810148,0.0002572225,0.005163766,0.01025098,0.00001215933,0.00256501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003986363,"threshold_uncertainty_score":0.0133357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01526134839490754,"score_gpt":0.2661466598261347,"score_spread":0.2508853114312271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}